What Changed at Techcyte

Every material change AI Health Index has tracked at Techcyte: new modules, model and architecture updates, clinical evidence, regulatory status, security certifications, and integration depth. Each entry states what changed, cites its source, and carries our read on what it means for a buyer. The graded assessment of this vendor across all fifteen capability axes sits on its index profile.

Funding rounds, valuations, and awards are not product changes and are not logged here. Acquisitions appear only where there is direct product impact.

Impact
Type
1 entry
Showing changes for Techcyte only.Show the full log

August 2026

T
Techcyte
Aug 12, 2026
HighVerified
Clinical evidence

A retrospective clinical evaluation study published in the Journal of Clinical Microbiology validated the diagnostic performance of Techcyte's Human Fecal Ova & Parasite Detection Wet Mount Iodine Solution. The artificial intelligence software, used alongside operator review, achieved a 96.62% positive percent agreement and a 93.33% negative percent agreement for detecting protozoan and helminthic infections in stool specimens.

Our read

The published findings provide strong independent validation that the artificial intelligence screening software maintains high diagnostic agreement with traditional microscopy while streamlining laboratory workflows. For microbiology labs, this clinical evidence supports the system's utility as a complementary tool that can reduce manual screening times and help uncover additional parasitic infections.

Related axis: Clinical and Operational EvidencePeer-reviewed publicationView source